NCT07241975 - Real-world Experience With the Available Outpatient COVID-19 Therapies in Patients With Cancer: an Ambispective Cohort Study | Crick

Overview

The real-life efficacy of early antiviral therapies in cancer patients with COVID-19 is largely uncharacterized. From these unresolved issues, it is therefore necessary to fill these knowledge gaps by assessing the efficacy and safety of these therapies in combination with anti-cancer therapies.

Study Type

OBSERVATIONAL

Enrollment

112

Conditions

Cancer Patients in Treatment Active Who Receive Early Out-patient Therapy Against SARS-CoV-2

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients ≥ 18 years diagnosed with and/or treated for solid tumors at the department of Oncologia of the Fondazione IRCCS Policlinico San Matteo 2. Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document 3. Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease Exclusion Criteria: * Patients who are unable to understand informed consent document

Locations (1)

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, Pavia, Italy

Outcomes

Primary Outcomes

evaluate the rate of hospitalization for COVID-19 disease within 14 days in the patients with cancer using COVID-19 early therapies as per indication.